证券之星消息，根据市场公开信息及11月4日披露的机构调研信息，广发基金近期对4家上市公司进行了调研，相关名单如下： 1）亚辉龙 （广发基金参与公司业绩说明会&券商电话会） 调研纪要：2025年第三季度，公司实现营业收入3亿元、归母净利润1.14亿元，剔除政府补贴及其他投资收益影响后净利润同比增长60%。国内前 三季度销量增速保持在20%以上，受集采影响收入基本持平。毛利率环比提升，主因生产效率提高与成本优化，预计全年毛利率恢复至70%以 上。海外收入同比增速超65%，占比提升至18%。Hector?计划11月开展国内多中心临床植入，已在欧洲获定制许可并启动销售。Cratos?覆盖约50 家临床中心，反馈良好。海外多款产品加速放量，国际业务毛利率提升至50%以上。 4）中联重科 （广发基金参与公司业绩说明会&线上） 个股亮点：公司拥有一个国家A级、国际T3+级的超算中心，现有GPU算力59P，支持1000个机柜，1万个服务器和混合云算力弹性扩展。；公司的 隧道掘进机械等设备可用于水利项目建设；中联重科作为全球领先的高端装备制造企业，与项目相关的承建方多年来有长期战略合作伙伴关系， 有望深度参与项目建设的核心环节 ...

Group 1: Gao Weida (高伟达) - Gao Weida achieved operating revenue of approximately 520.21 million yuan and a net profit of 13.83 million yuan in the first half of 2025, with a second-quarter net profit of 24.37 million yuan, reflecting a quarter-on-quarter growth of 231.19% [1] - The company is leveraging large model technology to implement multiple AI projects in credit scenarios, enhancing business revenue and exploring new development opportunities [1] - The new business model focuses on providing full lifecycle management for retail credit, rapidly increasing credit scale and managing non-performing assets, shifting from customized development to an operational model with a revenue-sharing approach [1] Group 2: Yahui Long (亚辉龙) - Yahui Long has completed the prototype of its second-generation sequencing project, achieving full self-research and production of core reagents, auxiliary reagents, and auxiliary enzyme reagents [2] - The company is advancing the integration of its product matrix, technology research and development, customer service, and office data with AI platforms like DeepSeek, enhancing laboratory automation [2] Group 3: Haoyang Co., Ltd. (浩洋股份) - Haoyang reported revenue of approximately 522 million yuan in the first half of 2025, a year-on-year decline of 21.99%, and a net profit of 7.8 million yuan, down 61.69% year-on-year [2] - Following the acquisition of Danish SGM company assets, Haoyang has established subsidiaries in Denmark and the United States, with positive market feedback on new product sales [2] - The company anticipates growth in overseas performance activities over the next two years, with expectations for the U.S. market to gradually recover, enhancing its R&D capabilities to improve competitiveness [2] Group 4: Zhonggeng Fund (中庚基金) - Zhonggeng Fund, established in 2015, has an asset management scale of 11.607 billion yuan, ranking 140th out of 210 in total public funds [3] - The fund's best-performing product in the past year is the Zhonggeng Hong Kong Stock Connect Value Fund, with a latest net value of 1.21 and a growth of 58.62% over the past year [3]